GeneOne Life Science, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeneOne Life Science, Inc.
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate.
As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.
Former BARDA leader says science not politics has to lead COVID-19 decision making. Plus Bayer launches Canada partnership, Korea pools research efforts.
- Contract Research, Toxicology Testing-CRO
- Consulting Services
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- VGXI, Inc.